Experience with Bevacizumab in Neuroendocrine Tumors
#1094
Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.
Aim(s): To analyze the efficacy and toxicity of bevacizumab-containing protocols in NET.
Materials and methods: We performed a retrospective analysis of all patients treated with bevacizumab-containing protocols for metastatic NET who presented at our center between August 2008 and December 2014.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Apostolidis L
Authors: Apostolidis L, Jäger D, Winkler E,
Keywords: neuroendocrine tumor, targeted therapy, bevacizumab, anti-angiogenesis,
To read the full abstract, please log into your ENETS Member account.